In homozygous P-thalassemia, studies of red cell membrane components have demonstrated a marked increase in malonyldiThis report the results of studies performed in aldehyde formation (12) . together with a significant decrease in patients with homOz~gous flethalassemia platelet func-the unsaturated fatty acid, arachidonic acid (9). These changes tion and prostaglandin formation. Platelet malonyldialdehyde appear to be indicative of red cell membrane lipid peroxidation.
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(MDA) formation in the presence of ethyl maleimide (NEM Oxidation and precipitation of excess a hemoglobin subunits, and mM) Or thrombin (0.5 u/ml) was used as an of platelet intracellular iron overload resulting in free radical generation are prostaglandin synthesis-The data on the nine patients revealed believed to be the major causes for this propensity to peroxidation two distinct subgroups of patients. Six of nine thalassemics, in the thalassemic red cell. In platelets, free radical formation is demonstrated platelet abnormalities. Their mean bleeding time important intermediate step in the conversion of arachidonic was 7.5 2 2.5 min (1 SD), significantly prolonged ( P < 0.005) when acid to the endoperoxides and thromboxanes involved in platelet to a value of 3.5 * min in contds. MDA aggregation (14) . This report details the results of studies performation in the Presence of NEM was significantly decreased (P formed in nine patients with homozygous P-thal-mia evaluat-< 0.0°5) 2.41 * 0.49 SD) when 'Ompared a contrd value ing platelet function and platelet prostaglandin formation. of 3.24 f 0.33 nmoles MDA/1OS platelets. Similarly, the mean value for thrombin induced MDA was 0.M f 0.18 nmdes which was decreased ( P < 0.02) when compared to a value of 1.26 2 0.2 MATERIALS AND METHODS in the controls. Platelet aggregations with adenosine diphosphate ~l o o d samples were obtained after informed consent from nine (ADPI, epinephrine, and collagen were dmormal in six patients. subjects with homozygous 8-thalassemia (eight with thalassemia However, when platelets from these patients were mixed with major and one with thalassemia intermedia- Table I ) and from platelets from donors who had ingested aspirin 2-8 hr before nine control subjects. Ages of the patient and control groups donation mutual correction and secondary irreversible aggregation varied between 3-24 and 5-28 yr, respectively. No control or of the mixture resulted. No mutual correction was observed when patient had ingested any medication known to affect platelet the thalassemic platelets were preincubated with aspirin in vim function for 10 days before blood donation. Six of nine thalassemic before mixing with platelets from donors who had recently ingested subjects were on no medication at the time of study, while three aspirin. Although the total amount of platelet malonyldialdehyde were on continuous subcutaneous infusion of the iron chelator formed by the thalassemic platelets in response to NEM desfemoxamine (Table 1) . The studies were performed pretransthrombin was decreased when compared to normal controls, this fusion in all nine thalassemic subjects at hemoglobin concentrareduction was not the cause of the platelet aggregation abnormal-tions ranging between 9.6-10.5 g/dl. Blood was also drawn conities. This appears to be so because the amount of MDA, Pad, temporaneously from nine controls who had ingested 600 mg of thus, prostaglandin endoperoxides synthesized by these platelets acetyl salicylic acid (ASA) 2-12 hr before blood donation. All in response to external stimuli was sufficient to cause irreversible blood samples were anticoagulated with 0.1 M buffered &rate aggregation of platelets from donors who had recently ingested anticoagulant in a ratio of 9 parts of blood to I part citrate. aspirin, and were, therefore, unable to synthesize their own endogPlatelet counts were performed using a Technicon platelet enous platelet endoperoxides. In the remhing three patients, analyzer. Platelet sizing was performed from blood smears prebleeding times, platelet aggregation, and MDA formation was pared from the EDTA-vacutainer tubes by the method of Rivard normal. No correlation was observed between the platelet abnor-and Lazerson (10) where platelet diameters were compared to malities nded and the magnitude of iron overload, presence of standard-sized polystyrene spheres. Platelet aggregation studies fibrin degradation products, liver function abaormlllities, or the were performed using platelet-rich plasma (PRP) prepared by use of iron chelators in the individual patient. Family studies were centrifuging the citrated blood at 150 g (800 rpm) at 22' C for 8 normal. Although the platelet dysfunction does not aPPear to be of min and adjusting the platelet count to approximately 200 X lo9/ major significance in the usual patient with thalassemia major liter. The aggregating agents employed included ADP (4 pM final under normal circumstances, antiplatelet aggregating agents concentration), epinephrine (6.2 pM final concentration), and should be used with caution. Aspirin inhibits platelet endoperoxide collagen suspensions. Concentrations of aggregating agents were and prostaglandin formation and this effect may potentiate the chosen that produced irreversible aggregation of control platelets. platelet dysfunction present in some patients with thalassemia Aggregation studies were performed on the nine control and nine major.
thalassemic PRPs, as also on the PRPs obtained from the nine volunteers who had ingested aspirin. After these aggregation Speculation studies, mixing experiments were performed in all six experiments where the initial studies revealed abnormalities in the thalassemic Platelet dysfunction in homozygous &thalassemia does not patients. For these studies, various proportions of normal or appear to be due to the decrease in platelet malonyldialdehyde thalassemic PRP (25.50, and 75%) were mixed with PRP obtained formation and, thus, platelet endoperoxide formation. The platelet from the aspirin donors (75, 50, and 25%) and the aggregation dysfunctional state may be liked with a plasma inhibitory effect. studies repeated. Finally, aspirin from a stock solution (I mM at ' T.I. = Homozygous P-thalassemia intermedia.
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" N D = not done. pH 7.4) was added in vitro in these six experiments to either control or thalassemic blood PRP, made up to a final aspirin concentration of 100 pM, and incubated for 15 min. After this incubation period, mixing experiments were repeated where 25% of these in vitro aspirin incubated normal or thalassemic PRPs were mixed with 75% PRP obtained from the aspirin donors. The PRP was kept in full, tightly-capped plastic test tubes before use, and all aggregating studies were performed within 120 min of platelet harvesting. Platelet lipid peroxide or MDA formation in the presence of NEM I mM or thrombin (0.5 units/ml) was performed by a modification (13) of the method of Okuma et al. (7) where the products of lipid peroxidation were measured as MDA after its reaction with 2-thiobarbituric acid. Bleeding times were performed by a modification of the Ivy Technique (6) . In the patient group prothrombin, partial thromboplastin, thrombin times, and liver function studies were performed by standard techniques. Fibrin degradation products (FDP) were evaluated by the technique of Merskey et al. (5) . and vitamin E levels by the method of Quaife et al. (8) .
Finally, platelet function studies (bleeding times, aggregations. and malonyldialdehyde formation induced by NEM and thrombin) were also performed on the parents of the two thalassemics with the most significant platelet functional abnormalities (M.T. and E.M.).
RESULTS

PLATELET DIAMETER DISTRIBUTION VALUES OF CONTROL VERSUS THALASSEMIC BLOOD
No significant shift in platelet diameter distribution values was observed in the patient population, when compared to a normal control population.
: of nine) with abnormal platelet function
EVALUATION OF PLATELET FUNCTION IN CONTROLS AND IN THALASSEMIC PATIENTS
The data on the nine patients revealed two distinct subgroups of patients. In three of nine patients with thalassemia (group A), all platelet function studies were normal when compared to the controls. The modified Ivy bleeding time in the nine normal controls was 3.5 * I min (mean * 1 SD). In patients M.S., R.K., and R.K. bleeding times were within the normal range with values of 4.5, 2, and 2.5 min, respectively. The normal controls demonstrated mean values of 3.24 * 0.33 (I SD), and 1.26 * 0.2 (I SD) nmoles MDA/1Og platelets after exposure of their platelets to I mM NEM or 0.5 u thrombin/ml, respectively. In the three of nine thalassemics (group A), values for platelet MDA formation with both NEM and thrombin were within the normal range. In these same three patients, platelet aggregations with ADP (4 pM) and epinephrine (6.2 pM) were normal, with biphasic irreversible aggregation similar to that of the control PRPs. Aggregation with collagen was also normal.
However, the remaining six of nine patients with homozygous P-thalassemia (group B) demonstrated a variety of platelet functional abnormalities as depicted in Table 2 . The mean bleeding time in this group of patients was 7.5 * 2.5 min (I SD). which was significantly prolonged ( P < 0.005) when compared to a value of 3.5 * 1.0 min in the normal controls. These patients also demonstrated a significant decrease in platelet MDA formation in the presence of either NEM or thrombin when compared to the normal controls. Mean value for NEM induced MDA formation was 2.41 f 0.49 (1 SD) nmoles MDA/IOY platelets, which was significantly decreased ( P < 0.005) when compared to the value in the control group of 3.24 f 0.33 nmoles. Similarly, the mean value for thrombin induced MDA was 0.98 f 0.18 nmoIes/lOg platelets which was decreased ( P < 0.02) when compared to a value of 1.26 f 0.2 in the controls. Platelet aggregations were abnormal in all six patients in this group with minimal first wave aggregation with ADP and epinephrine, and minimal aggregation to collagen <30% of concomitant control PRP. Figure I depicts representative platelet aggregation tracings of normal control versus thalassemic PRP using ADP (4 pM), epinephrine (6.2 pM), and collagen as aggregating agents.
As expected, PRP from the control donors who had ingested aspirin 2-8 hr before donation demonstrated only first wave aggregation with ADP and epinephrine, and minimal aggregation to collagen. These ASA donors had markedly decreased values of 0.27 k 0.15 (1 SD) and 0.10 k 0.08 nmoles MDA/IOS platelets after exposure of the platelets to NEM and thrombin, respectively.
In an attempt to normalize the aggregation patterns of the six thalassemic PRPs (group B) and that obtained from the aspirin donors, mixing studies were performed. Mixing of 75% aspirin donor PRP with 25% thalassemic PRP caused complete normalization of the resultant mixture in all six experiments using ADP (4 pM), epinephrine (6.2 pM) and collagen. Similar normalization of aggregation tracings was obtained when mixing studies were performed with 50% aspirin donor PRP and 50% thalassemic PRP. However, correction of aggregation tracings was not obtained when the mixture contained 25% aspirin donor PRP and 75% thalassemic PRP. No correction was obtained with ADP, epinephrine, or collagen in all six experiments when 25% PRP from the six abnormal thalassemic patients was incubated in vitro with aspirin before mixing with 75% PRP obtained from aspirin donors. When control PRP was similarly incubated in vitro with aspirin before mixing with PRP obtained from aspirin donors no correction was also observed. Figure 2 is a composite of superimposed platelet aggregation tracings demonstrating abnormal aggregation in response to 4 pM ADP in both the thalassemic and ASA control. Mutual correction is observed in mixing experiments where 75% ASA control PRP (0.3 ml) is mixed with 25% thalassemic PRP (0.1 ml) before addition of the aggregating agent. It will also be noted in this graph that no mutually corrective effect was observed when the ratios were reversed, i.e., 25% ASA control PRP (0.1 ml) was mixed with 75% thalassemic PRP (0.3 ml) before the addition of the aggregating agent. Fig. 2 . Aggregating tracings of aspirin donor platelets and those from a patient with homozygous P-thalassemia demonstrating abnormal aggregation with ADP (4 pM) in both cases. Normalization of the tracing is seen in the mixing experiment where 0.3 ml (75%) aspirin control PRP is mixed with 0. I ml (25%) thalassemic PRP. No correction of the tracing is -seen in the mixing experiment where 0.1 m1 (25%) aspirin control PRP is mixed with 0.3 m1 (75%) thalassemic PRP.
COAGULATION SCREENING TESTS. LIVER FUNCTION STUDIES. AND PLASMA VITAMIN E LEVELS IN CONTROLS VERSUS THALASSEMIA
BLOOD cant decrease was noted in plasma vitamin E levels in the patient
No abnormalities were noted in the prothrombin, partial throm-group as a whole ( P c 0.01) with a mean level of 0.77 * 0.29 (1 boplastin, or thrombin times in the patients with homozygous P-SD) mg/dl when compared to the control value of 1.27 + 0.4 mg/ thalassemia. FDP were also normal in all nine patients. A signifi-dl. Liver function abnormalities were found in all thalassemic patients and included elevations of SCOT (nine of nine) and total bilirubin (three of nine).
PLATELET FUNCTION STUDIES IN PARENTS OF GROUP B THALASSEMICS
Studies in all four parents evaluated were normal. Mean bleeding time was 4.1 -+ 1. I min (I SD). Platelet MDA formation in the presence of both NEM and thrombin was normal at 3.21 k 0.09 and 1.22 k 0.18 nmoles/ l @\platelets, respectively. Platelet aggregations with ADP (4 pM), epinephrine (6.2 pM), and collagen were also normal.
DISCUSSION
The results of the present study show that out of nine patients with homozygous P-thalassemia evaluated, six demonstrated olatelet functional abnormalities. The abnormalities included Drolongation of bleeding times, abnormal aggregations with ADP, epinephrine, and collagen, and decreased formation of platelet MDA, in the presence of both NEM and thrombin. ~h e s e laboratory findings were not associated with a clinically significant bleeding tendency in these six patients. However, a history of epistaxis and petechial rashes in the presence of normal platelet counts have been occasionally observed in patients with homozygous P-thalassemia (4) .
Basic mechanisms of platelet function include adhesion, contraction, and secretion of platelet constituents contained in platelet dense bodies and a granules. An impairment in secretion can be due to a reduction of serotonin and the nonmetabolic pool of platelet adenine nucleotides, i.e., a storage pool defect, or due to an impairment of prostaglandin synthetic ability, although platelets in this latter situation usually contain a normal complement of serotonin and storage pool nucleotides. In both types of abnormalities the second wave of platelet aggregation is absent such that the performance of platelet aggregation studies will not elucidate the type of defect present.
Smith et al.
(1 I) has demonstrated that platelet MDA (a byproduct of the platelet endoperoxides) may be used as an indicator of platelet prostaglandin synthesis. Prostaglandin biosynthesis appears to play a key role in platelet secretion and the second wave of platelet aggregation. After various aggregating stimuli, phospholipase is activated in the platelet membrane, which leads to the splitting of arachidonic acid from platelet membrane phospholipid. Prostaglandin cyclooxygenase catalyzes the synthesis from arachidonic acid of the labile endoperoxides PGG2 and PGHa. These endoperoxides in the presence of thromboxane synthetase (an enzyme present in platelet microsomes) causes the synthesis of thromboxane AS. the most potent inducer of platelet aggregation and release yet identified. In these studies, determination of platelet MDA formation with NEM and thrombin revealed that the donors who had recently ingested aspirin manifested a near complete absence of platelet malonyldialdehyde formation, concomitant with abnormal single wave reversible platelet aggregation. Platelet aggregation tracings in the six of nine group B thalassemic patients were similar to the aspirin donors. However, although the total amount of platelet MDA formed by these thalassemic platelets in response to NEM and thrombin was decreased when compared to normal controls, this reduction was not the cause of the platelet aggregation abnormalities. This appears to be so because the amount of MDA, and, thus, prostaglandin endoperoxides synthesized by these platelets in response to external stimuli was sufficient to cause irreversible aggregation of platelets from donors who had recently ingested aspirin, and were, therefore, unable to synthesize their own endogenous platelet endoperoxides. The absence of complete and irreversible aggregation when a mixture of platelets from aspirin donors was combined with thalassemic platelets preincubated with aspirin in vitro also serves to demonstrate that the thalassemic platelet dysfunction cannot be attributed to the abnormality in prostaglandin synthesis. The mixing studies are based on those of Gerrard et al. (2) who have elegantly demonstrated that platelets from patients with the Hermansky-Pudlak syndrome (adenine nucleotide storage pool deficient) correct the defective aggregation and release of aspirin-treated normal platelets by releasing sufficient amounts of platelet endoperoxides to cause aggregation of the aspirin platelets.
In the only previous abstract in the literature, Markenson and Hilgartner (4) demonstrated abnormal bleeding times in 3 of 30, and abnormalities in platelet aggregation in 13 of 30 patients with P-thalassemia major. They showed that the dysfunction appeared to be due to a plasma factor by demonstrating that normal donor gel filtered platelets were made functionally abnormal when incubated in platelet poor plasma from the thalassemic patients who had manifested platelet dysfunction. In this study, no correlation was observed between the platelet dysfunctional state and liver function studies, the presence of FDP, the use of an iron chelator, or the magnitude of iron overload in the individual patient. From Tables 1 and 2 , it will be seen that the most severe platelet dysfunctional state was seen in M.T., the youngest patient, who has received the least number of red cell transfusions, who is not receiving an iron chelator, and who has the lowest ferritin level of the group as a whole. That the platelet dysfunctional state is not directly related to iron deposition in platelets was also shown by Markenson and Hilgartner (4) who analyzed the thalassemic platelet spectrophoto~etrically for iron with negative results. Hereditarv causes for the platelet functional abnormalities were also ruled out by our family studies.
Low serum levels of vitamin E have been previously demonstrated in thalassemia major (9) , with the suggestion that the low levels are due to a secondary consumption of the antioxidant due to membrane oxidation. However, serum a-tocopherol levels do not correspond with red cell MDA values after peroxide exposure (12) , and thalassemic patients with the most significant membrane lipid abnormalities were those with the longest intertransfusion interval (9) . Because the E deficient state has been associated with platelet hyperaggregability (3) . the platelet hypofunction in these thalassemic patients cannot be attributed to the concomitantly present E dekciency.
Unlike the red cell, the platelet in thalassemia major does not demonstrate an increase but rather a decrese in MDA formation. This is interesting in light of the previous red cell studies of Rachmilewitz et al. (9) who demonstrated a decrease in aracbidonic acid in the red cell membrane in thalassemia, suggesting that peroxidation of membrane may have occurred. In the platelet, because arachidonic acid is the main substrate for platelet endoperoxide and prostaglandin synthesis, it is possible that decreased levels of this polyunsaturated fatty acid, if present in the platelet membrane in thalassemia, will ultimately lead to decreased endoperoxide and prostaglandin formation.
The bleeding time is the most important in vivo assay of platelet adhesion and aggregation available at the present time. It is suggested that bleeding times be performed on all patients with thalassemia before surgical procedures. The platelet dysfunction does not appear to be of much clinical significance in the usual patient with thalassemia major under normal circumstances. It is well documented, however, that the ingestion of aspirin can markedly prolong the bleeding time in subjects with underlying abnormalities either in platelet function, or in the fluid phase of coagulation (1). Aspirin inhibits platelet endoperoxide and prostaglandin formation. Because the inhibition of platelet endoperoxide formation may potentiate the platelet dysfunction already present in some patients with thalassemia major, this drug should be used with caution in this disorder.
